Advertisement
Journal Home
Search for

Articles in Press

Return to articles in press list

Involvement of LKB1 in epithelial–mesenchymal transition (EMT) of human lung cancer cells

Badal C. Roya, Takashi Kohnoa, Reika Iwakawaa, Tetsuo Moriguchia, Tohru Kiyonob, Kazuhiro Morishitac, Montse Sanchez-Cespedesd, Tetsu Akiyamae, Jun YokotaaCorresponding Author Informationemail address

Received 19 November 2009; received in revised form 5 February 2010; accepted 8 February 2010. published online 08 March 2010.
Corrected Proof

Abstract 

Epithelial–mesenchymal transition (EMT) is a critical phenotypic alteration of cancer cells that triggers invasion and metastasis. Lung cancer cells often show mesenchymal phenotypes; however, a causative genetic alteration for the induction of EMT in lung cancer cells remains unknown. Recent studies have shown that the LKB1 gene is mutated in up to one-third of lung adenocarcinomas. Therefore, to pursue the possible involvement of LKB1 inactivation in the induction of EMT in lung carcinogenesis, we generated immortalized lung epithelial cells and lung adenocarcinoma cells with stable or transient LKB1 knockdown. LKB1 knockdown increased cell motility and invasiveness, and induced the expression of several mesenchymal marker proteins accompanied by the expression of ZEB1, a transcriptional repressor for E-cadherin and an EMT inducer. In agreement with the recent findings, expression of miR-200a/c was inversely correlated with that of ZEB1 in LKB1 knockdown clones with mesenchymal phenotype. Furthermore, transient knockdown of LKB1 induced ZEB1 mRNA and increased cell motility, and this motility was suppressed by ZEB1 repression. These results strongly indicate that LKB1 inactivation triggers EMT in lung cancer cells through the induction of ZEB1.

a Biology Division, National Cancer Center Research Institute, 1-1, Tsukiji 5-chome, Chuo-ku, Tokyo, 104-0045, Japan

b Virology Division, National Cancer Center Research Institute, Tokyo, 104-0045, Japan

c Division of Tumor and Cellular Biochemistry, Department of Medical Sciences, University of Miyazaki, Miyazaki, Japan

d Genes and Cancer Group, Programa de Epigenetica y Biologia del Cancer (PEBC), Institut d’Investigacions Biomediques Bellvitge (IDIBELL), Hospital Durant i Reynals, Avinguda Gran Via de I’Hospitalet, 199-203, 08907-L’Hospitalet de Llobregat, Barcelona, Spain

e Laboratory of Molecular and Genetic Information, Institute of Molecular and Cellular Bioscience, University of Tokyo, Tokyo, Japan

Corresponding Author InformationCorresponding author. Tel.: +81 3 3547 5272; fax: +81 3 3542 0807.

PII: S0169-5002(10)00069-3

doi:10.1016/j.lungcan.2010.02.004